Advice

following a full submission:

relugolix, estradiol, norethisterone acetate tablets (Ryeqo®) is accepted for restricted use within NHSScotland.

Indication under review: treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

SMC restriction: for use in patients who have failed or are unsuitable for conventional therapies (first line treatments), such as tranexamic acid, hormonal contraceptives and intrauterine delivery systems.

Relugolix, estradiol, norethisterone acetate tablets (Ryeqo®), compared with placebo, significantly reduced menstrual blood loss volume in patients with uterine fibroids and heavy menstrual bleeding.

Medicine details

Medicine name:
relugolix/estradiol/norethisterone acetate (Ryeqo)
SMC ID:
SMC2442
Indication:

For treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Pharmaceutical company
Gedeon Richter UK Ltd
BNF chapter
Obstetrics, gynaecology, and urinary-tract disorders
Submission type
Full
Status
Restricted
Date advice published
13 June 2022